SCM
BMY.RT

Symons Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Symons Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,784
Closed -$24K – 99
2020
Q4 		$24K Sell
34,784
-616
-2% -$1.31K 0.01% 83
2020
Q3 		$79K Sell
35,400
-936
-3% -$2.67K 0.05% 80
2020
Q2 		$130K Sell
36,336
-522
-1% -$1.88K 0.08% 71
2020
Q1 		$139K Sell
36,858
-637
-2% -$2.1K 0.08% 74
2019
Q4 		$113K Buy
+37,495
New +$97.5K 0.06% 66

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Symons Capital Management's BMY.RT Position: Q1 2021 in Review

Symons Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 34,784 shares — an estimated $24K sold.

Symons Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $139K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Symons Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Symons Capital Management sold 34,784 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $24K.
  • Symons Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Symons Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $139K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Symons Capital Management's 13F filing for Q1 2021, filed 4 May 2021.